These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23284776)

  • 61. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Insulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials.
    Freemantle N; Meneghini L; Christensen T; Wolden ML; Jendle J; Ratner R
    Diabet Med; 2013 Feb; 30(2):226-32. PubMed ID: 23199058
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Glycemic variation and hypoglycemia in patients with well-controlled type 1 diabetes on a multiple daily insulin injection program with use of glargine and ultralente as basal insulin.
    Kudva YC; Basu A; Jenkins GD; Pons GM; Vogelsang DA; Rizza RA; Smith SA; Isley WL
    Endocr Pract; 2007; 13(3):244-50. PubMed ID: 17599855
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Insulin degludec. Uncertainty over cardiovascular harms.
    Prescrire Int; 2014 Jun; 23(150):149. PubMed ID: 25121146
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta-analysis.
    Joshi SR; Singh G; Marwah A; Mittra S; Suvarna VR; Athalye SN
    Diabetes Obes Metab; 2023 Jun; 25(6):1589-1606. PubMed ID: 36748186
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
    Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
    Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
    JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Insulin glargine clinical trials.
    White JR
    Clin Ther; 2004 Jul; 26(7):1179-81; discussion 1182-3. PubMed ID: 15336483
    [No Abstract]   [Full Text] [Related]  

  • 69. Basal insulin and cardiovascular and other outcomes in dysglycemia.
    ; Gerstein HC; Bosch J; Dagenais GR; Díaz R; Jung H; Maggioni AP; Pogue J; Probstfield J; Ramachandran A; Riddle MC; Rydén LE; Yusuf S
    N Engl J Med; 2012 Jul; 367(4):319-28. PubMed ID: 22686416
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
    Testa MA; Gill J; Su M; Turner RR; Blonde L; Simonson DC
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3504-14. PubMed ID: 22851487
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
    Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
    Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
    Kvapil M; Žďarská DJ; Suchopár J; Prokeš M; Brož J
    Vnitr Lek; 2015 Jan; 61(1):24-32. PubMed ID: 25693613
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients.
    Morden NE; Liu SK; Smith J; Mackenzie TA; Skinner J; Korc M
    Diabetes Care; 2011 Sep; 34(9):1965-71. PubMed ID: 21775752
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.
    Arakaki RF; Blevins TC; Wise JK; Liljenquist DR; Jiang HH; Jacobson JG; Martin SA; Jackson JA
    Diabetes Obes Metab; 2014 Jun; 16(6):510-8. PubMed ID: 24298995
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes.
    Joseph JJ; Donner TW
    Vasc Health Risk Manag; 2015; 11():107-16. PubMed ID: 25657589
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence.
    Bronsveld HK; ter Braak B; Karlstad Ø; Vestergaard P; Starup-Linde J; Bazelier MT; De Bruin ML; de Boer A; Siezen CL; van de Water B; van der Laan JW; Schmidt MK
    Breast Cancer Res; 2015 Aug; 17(1):100. PubMed ID: 26242987
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Insulin analogues and cancer risk: the emergence of second-generation studies.
    Renehan AG
    Diabetologia; 2012 Jan; 55(1):7-9. PubMed ID: 22033621
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparative effectiveness and harms of long-acting insulins for type 1 and type 2 diabetes: A systematic review and meta-analysis.
    Holmes RS; Crabtree E; McDonagh MS
    Diabetes Obes Metab; 2019 Apr; 21(4):984-992. PubMed ID: 30552792
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å; Pollock RF; Hunt B; Valentine WJ
    J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.